Tarsus Pharmaceuticals, Inc.
TARS
Peringkat dalam Saham
#4589
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$71.12
Kapitalisasi Pasar
$3.33B
Perubahan (1 hari)
2.33%
Perubahan (1 tahun)
-0.10%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Laba untuk Tarsus Pharmaceuticals, Inc. (TARS)
Laba pada Jun 2026 TTM: $-44.05M
Menurut laporan keuangan terbaru dari Tarsus Pharmaceuticals, Inc., laba saat ini perusahaan adalah $-44.05M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-135.89M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-62.10M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-44.05M | -61.88% |
| 2024 | $-115.55M | -14.97% |
| 2023 | $-135.89M | 118.85% |
| 2022 | $-62.10M | 350.88% |
| 2021 | $-13.77M | -48.63% |
| 2020 | $-26.81M | 474.21% |
| 2019 | $-4.67M | 254.25% |
| 2018 | $-1.32M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -12,073.99% |
US
|
|
| $-3.09B | 6,907.47% |
US
|
|
| $-4.02B | 9,016.74% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -4,527.96% |
NL
|
